Pfizer's obesity pill news leaves analysts wantingThe New...

Pfizer's obesity pill news leaves analysts wanting

The New York-based Big Pharma is hoping to recover from earlier data that showed a twice-daily formulation of oral danuglipron led to modest weight loss with a HIGH LEVEL OF ADVERSE EVENTS AND PATIENT DISCONTINUATIONS.

Now, the company is looking to advance the med as a once-daily, modified-release formulation on the strength of “encouraging pharmacokinetic data.

SUMMARY:

Lab Technician: "The bloody thing is not working, participant's are getting really sick and pulling out of the trials"

Albert Bourla: "Make it work, fudge the figures, just do what you have to do. We need a slice of the obesity market pie until those Covid Vaccines really kick in, then we'll smash it out of the park with our cancer drugs."

https://www.fiercebiotech.com/biotech/pfizers-obesity-pill-news-leaves-analysts-wanting-biotech-investors-cheering